MedPath

Feasibility stuydy of S-1 and weekly cisplatin in patients received R0 resection for Stage IIB and III gastric cancer

Not Applicable
Conditions
gastric cancer
Registration Number
JPRN-UMIN000005600
Lead Sponsor
Hamamatsu Organization for Oncology Research and Education : HORE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 2) administration contraindication to S-1 and CDDP 3) systemic administration of corticosteroids, flucytosine, phenytoin or warfarin 4) with active infection 5) with drug hypersensitivity 6) other severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, regular use of insulin or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 7) with water solubility diarrhea 8) pregnant or lactating women, women who are capable of pregnancy or intend to get pregnant 9) men with willing to get pregnant 10)Any other cases who are regarded as inadequate for study enrollment by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath